Additional small molecules shown to potentially act through TFEB activation are PARP1 inhibitors, such as Veliparib in an α-Syn mouse model [220] or trifluoperazine, an inhibitor of calmodulin and dopamine D2 receptor, in Pink1 deficiency and rotenone-induced zebrafish models with PD-like symptoms [210]. The gene discussed is TFEB; the disease is Parkinson disease.